Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + S-1 maintenance after first-line therapy for advanced biliary tract cancer
ChiCTR2000035590Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and tegafur in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by West China Hospital of Sichuan University. Primary endpoints: progression-free survival and overall survival. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
sintilimabtegafur
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2000035590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035590.